As the buzz around GLP-1 medications grew over the past two years, many digital health companies rushed to offer prescription programs. Omada Health instead focused on strengthening its weight management program and building a GLP-1 care track with wraparound support for members using these medications.
The virtual chronic care provider announced Thursday that it will begin prescribing GLP-1 drugs in 2026, with nationwide availability. The news came shortly after the White House revealed agreements with Eli Lilly and Novo Nordisk to sell weight loss drugs at lower prices.
“Omada is preparing for the next era of obesity care—one with broader access to GLP-1 medications,” said CEO Sean Duffy. “The conversation is shifting from ‘Can patients get these drugs?’ to ‘Can we help them use them effectively and safely for long-term outcomes?’”
Omada’s expanded GLP-1 program includes nutrition guidance, education, and support from trained providers across all 50 states. The move was driven by customer demand for integrated care that combines prescribing with behavior change, said President Wei-Li Shao.
Launched in 2023, Omada’s GLP-1 Care Track has supported more than 100,000 members. Company data show that 63% maintained or continued to lose weight a year after stopping GLP-1s.
Omada reported third-quarter revenue of $68 million, up 49% year-over-year, and achieved its first positive adjusted EBITDA quarter. Membership grew 53% to 831,000, prompting a raised full-year revenue outlook to $251.5–$254.5 million.
The company is also deepening its use of AI, including new tools like Meal Map and OmadaSpark for nutrition guidance, and generative AI for care and engineering teams. Looking ahead, Duffy said 2026 will be “the year of the Gs”—GLP-1s and GPTs—as Omada invests in both prescribing capabilities and AI to fuel sustainable growth.
Click here to read the original news story.